Activation of a Nodal-independent signaling pathway by Cripto-1 mutants with impaired activation of a Nodal-dependent signaling pathway  by Bianco, Caterina et al.
FEBS Letters 582 (2008) 3997–4002Activation of a Nodal-independent signaling pathway
by Cripto-1 mutants with impaired activation of a Nodal-dependent
signaling pathway
Caterina Bianco, Margaret Mysliwiec, Kazuhide Watanabe, Mario Mancino,
Tadahiro Nagaoka, Monica Gonzales, David S. Salomon*
Mammary Biology and Tumorigenesis Laboratory, NCI/NIH, 37 Convent Drive, Building 37 room 1112, Bethesda, MD 20892, USA
Received 11 September 2008; revised 23 October 2008; accepted 31 October 2008
Available online 18 November 2008
Edited by Lukas HuberAbstract Cripto-1, a co-receptor for Nodal, can activate No-
dal-dependent and Nodal-independent signaling pathways. In this
study we have investigated whether Cripto-1 mutants, that fail to
activate a Nodal-dependent signaling pathway, are capable to
activate a Nodal-independent signaling pathway in mammary
epithelial cells. Cripto-1 mutants expressed in EpH4 mouse
mammary epithelial cells are fully functional in regard to activa-
tion of a Nodal-independent signaling pathway, leading to phos-
phorylation of mitogen-activated protein kinase (MAPK) and
Akt and to enhanced proliferation and motility of these cells,
suggesting that Cripto-1 mutants with impaired Nodal signaling
are still active in a Nodal-independent signaling pathway.
Structured summary:
MINT-6797299:
Glypican 1 (uniprotkb:P35052) physically interacts (MI:0218)
with Cr 1 (uniprotkb:P13385) by anti bait coimmunoprecipita-
tion (MI:0006)
Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Human and mouse Cripto-1 (CR-1/Cr-1) are members of the
epidermal growth factor (EGF)–CFC (Cripto-1 in humans,
FRL1 in Xenopus and Cryptic in mice) family of proteins [1].
EGF–CFC proteins contain multiple domains including amod-
iﬁed EGF-like domain and a cystein-rich CFCmotif [1]. During
embryogenesis, Cripto-1 can function as a co-receptor for the
transforming growth factor b (TGFb) family member Nodal
regulating the formationof the primitive streak and speciﬁcation
of the mesoderm and endoderm [1]. Cripto-1-dependent Nodal
signaling depends upon the Activin type II (Act RII) and type
I (Alk4) serine/threonine kinase receptors that activate the
Smad-2/Smad-3 intracellular signaling pathway [2]. Evidence
suggests that Cripto-1 recruits Nodal to theAct RII/Alk4 recep-
tor complex by interactingwithNodal through theEGF-like do-*Corresponding author. Fax: +1 301 402 8656.
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expressed at high levels in several diﬀerent types of human tu-
mors, including breast and colon cancer [1]. In fact, Cripto-1
overexpression in human cancers has been associated with
numerous aspects of tumor initiation and progression, including
enhanced cellular proliferation, epithelial-to-mesenchimal tran-
sition and tumor angiogenesis [4–6]. Regulation of cell prolifer-
ation, motility and survival by Cripto-1 is dependent upon
activation of the ras/raf/mitogen-activated protein kinase
(MAPK) and phopshatidylinositol 3 0 kinase (PI3K)/Akt signal-
ing pathways [2,7]. Activation of these two intracellular signal-
ing pathways is independent of Nodal and is mediated by
binding of Cripto-1 to the heparan sulfate proteoglycan Glypi-
can-1, which can then activate the tyrosine kinase c-Src trigger-
ing activation of MAPK and Akt [7]. O-fucosylation is a rare
formof glycosylation inwhich fucose is transferred toThreonine
(Thr) or Serine (Ser) residues within an EGF-likemodule of sev-
eral proteins [8]. Human and mouse Cripto-1 proteins are
fucosylated at a conserved Thr residue within the EGF-like do-
main (Thr88 for human CR-1 and Thr72 for mouse Cr-1) [9–11].
A single point mutation in the fucosylation consensus sequence
of human CR-1 (Thr88 to alanine [Ala]) or of mouse Cr-1 (Thr72
to Ala) results in loss of Cripto-1-dependent Nodal signaling in
diﬀerent cell-based assays [9,11]. Interestingly, a recent study has
shown that O-fucosylation is not required by Cripto-1 to func-
tion in Nodal signaling pathway and that, in contrast, Thr72,
to which O-fucose is attached, is absolutely required by Cri-
pto-1 to bind toNodal [10]. However, none of these studies have
investigated whether O-fucose and/or Thr88/72 are required for
the activation of a Nodal-independent signaling pathway. In
the present study we have assessed the biological activity of
fucosylation impaired and/or Thr Cripto-1 mutants in Nodal-
independent signaling assays inmousemammary epithelial cells.
2. Materials and methods
2.1. Cell culture
EpH4, COS7 and 293T cells were grown as previously described [2].
EpH4 cells were transfected with wild-type, T72A and T72S Cripto-1
plasmids (kindly provided by Pamela Stanley, Albert Einstein College
of Medicine, New York) using Fugene 6 (Roche, Indianapolis, IN) and
cell lines were selected with G418 (400 lg/ml) (Invitrogen, Carlsbad,
CA) for 2 weeks [7].
2.2. Cell proliferation, migration and invasion assays
Proliferation assay was performed as previously described [6].
Migration and invasion assays were performed in ﬁbronectin-coatedEuropean Biochemical Societies.
Fig. 1. Expression of wild-type, T72A and T72S Cr-1 plasmids in
EpH4 cells. Western blot analysis for Cr-1 and b-actin in EpH4 cells
expressing Cr-1, T72A and T72S plasmids.
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Brieﬂy, EpH4 WT, Cr-1, T72A or T72S cells were seeded in 12-well
plates at 2 · 105 cells per well and incubated overnight at 37 C. The
following day, the cells that had migrated or invaded the Matrigel
through the ﬁlter were stained with a crystal violet solution, the stain
solution was eluted and the absorbance was read at 595 nm.
2.3. Western blot analysis
EpH4 WT, Cr-1, T72A and T72S cells were seeded in 60-mm plates
(5 · 105 cells/plate) and serum starved for 24 h. Western blot analysis
for phospho- and total-MAPK (1:1000 dilution, Cell Signaling, Bev-
erly, MA) and phospho- and total-Akt (1:1000 dilution, Cell Signaling)
was performed as previously described [2]. For Smad-2 activation,
EpH4 WT, Cr-1, T72A and T72S were transiently transfected with a
Nodal expression vector [12] using Fugene 6 and serum-starved for
24 h. Western blot for phospho- and total Smad-2 was performed
using anti-phospho- and total-Smad-2 antibodies (1:1000, Cell Signal-
ing). Western blots for Cr-1 and b-actin were performed using an anti-
mouse Cr-1 goat polyclonal antibody (1:1000, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA) and an anti-b-actin mouse monoclonal antibody
(1:10000, Sigma, St. Louis, MO).
2.4. Coimmunoprecipitation assay
COS7 cells (1 · 106 cells/60-mm plates) were transiently transfected
with Glypican-1-Fc and Cr-1, T72A or T72S expression vectors using
Fugene 6. 48 h after transfection cells were lysed and Glypican-1-Fc
was immunoprecipitated as previously described [7]. Western blots
were performed using anti-mouse Cr-1 goat polyclonal antibody (San-
ta Cruz) and anti-human Fc antibody (1:5000, Amersham, Piscataway,
NJ) for Glypican-1Fc.
2.5. Transfection of EpH4 cells with siRNA
EpH4 WT, Cr-1, T72A and T72S cells were transfected with 3 lg of
mouse Glypican-1 siRNA (Santa Cruz Biotechnology) or control siR-
NA (Santa Cruz Biotechnology) using Amaxa technology (Amaxa
Biosystems, Gaithersburg, MD). After nucleofection cells were plated
at 1 · 106 cells in 100-mm plates. The following day, plates for Western
blot analysis were washed with PBS and incubated in serum-free med-
ium for additional 24 h. 48 h after nucleofection, proteins were ex-
tracted from plates in serum-free medium and RNA was isolated
from plates of cells growing in complete medium. Western blot analysis
was then performed on serum-starved cells using phospho- and total-
MAPK or phospho- and total-Akt antibodies, as described above.
2.6. Real-time PCR
RNA was isolated using RNeasy mini kit (Qiagen, Valencia, CA)
and cDNA synthesis was performed using 1 lg of total RNA with
the RETROscript kit (Ambion Applied Biosystems, Foster City,
CA) following the manufacturers protocol. Quantitative Real time
PCR was performed on Startagene MX300P using Brilliant II SYBR
Green PCR master mix (Stratagene, Cedar Creek, TX). Primers for
mouse Glypican-1 were purchased from Santa Cruz Biotechnology.
Glypican-1 expression levels were normalized to mouse 28S RNA
expression (forward primer 5 0-TTGAAAATCCGGGGGAGAG-30,
reverse primer 5 0-ACATTGTTCCAACATGCCAG-3).
2.7. Luciferase assay
Nodal-responsive reporter assay was performed as previously de-
scribed [13]. Brieﬂy, 293T cells plated in 24-well plates were transfected
with an optimized amount of expression vectors ((n2)7-Lux, 50 ng/
well; TK-renilla (Promega, Madison, WI), 5 ng/well; FAST-1, 25 ng/
well; Nodal, 100 ng/well; Alk4, 50 ng/well; Cr-1, T72A or T72S,
100 ng/well). 24 h after transfection, dual-luciferase assays were per-
formed using a dual-luciferase kit (Promega).3. Results
3.1. Generation of EpH4 mouse mammary epithelial cells stably
expressing Cr-1 mutants
We have previously demonstrated that overexpression of
mouse Cr-1 can induce an increase in cell proliferation,anchorage-independent growth, migration and invasion of
mouse mammary epithelial cells [4]. We therefore investigated
the biological eﬀects of the Cr-1 T72A mutant, which is not
fucosylated, and the Cr-1 T72S mutant, which is fucosylated
on the Ser residue, in EpH4 mouse mammary epithelial cells,
which are negative for Cr-1 expression [4]. EpH4 wild-type
(WT) control cells were transfected with expression vectors
encoding for wild-type Cr-1 or T72A and T72S Cr-1 mutants.
A speciﬁc band for Cr-1 could be detected by Western blot
analysis in EpH4 Cr-1, T72A and T72S cells using an anti-
Cr-1 polyclonal antibody (Fig. 1).
3.2. Expression of wild-type, T72A or T72S Cr-1 enhance cell
proliferation, migration and invasion of EpH4 mammary
epithelial cells
To ascertain if overexpression of wild-type or mutant Cr-1
proteins might alter cell proliferation, EpH4 WT, Cr-1,
T72A and T72S cells were grown in serum-free conditions
for 7 days. In agreement with previous results [4], Cr-1 trans-
fected cells exhibited an approximately three-fold enhanced
growth rate after 6 days under serum-free conditions com-
pared to EpH4 WT control cells (Fig. 2A). EpH4 T72A or
T72S cells showed a proliferation rate similar to EpH4 Cr-1
cells (Fig. 2A). We next determined the eﬀect of T72A and
T72S Cr-1 mutants on EpH4 cell motility. As shown in
Fig. 2B and C, EpH4 Cr-1 expressing cells exhibited a statisti-
cally signiﬁcant increase in their migratory (three-fold in-
crease) (P < 0.01) and invasive (two-fold increase) (P < 0.01)
behavior when compared to EpH4 WT cells. Likewise, EpH4
T72A and EpH4 T72S cells also showed enhanced motility
with levels of migration and invasion comparable to EpH4
Cr-1 cells.
3.3. T72A and T72S mutants activate Nodal-independent
signaling pathways in EpH4 cells
We therefore investigated whether T72A or T72S Cr-1 mu-
tants were capable of activating MAPK and Akt signaling
pathways in EpH4 mammary epithelial cells. When cultured
in serum-free conditions, EpH4 Cr-1, T72A or T72S showed
Fig. 2. Biological activity of T72A and T72S Cr-1 mutants and activation of MAPK and Akt signaling pathways in EpH4 cells. (A) Proliferation
assay in serum-free conditions of Cr-1, T72A and T72S EpH4 expressing cells compared to wild-type control cells. Data are representative of three
experiments with triplicate samples. (B) Migration and (C) invasion assay of EpH4 WT, Cr-1, T72A and T72S cells. OD: optical density. The
absorbance is reﬂective of the number of migrating or invading cells. *P < 0.01. Data are representative of four experiments with duplicate samples.
Western blot analysis for phospho- and total-MAPK (D) and phospho- and total-Akt (E) in serum-starved EpH4 cells.
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tion of MAPK or four-fold increase in the phosphorylation of
Akt, after normalizing to total MAPK and Akt levels of
expression (Fig. 2D and E) as compared to EpH4 WT cells.
Similar results, with respect to cell proliferation, migration,
invasion and activation of intracellular signaling molecules,
were obtained in HC11 mouse mammary epithelial cells
expressing Cr-1, T72A or T72S plasmids (data not shown).
3.4. T72A and T72S Cr-1 mutants fail to activate a Nodal-
dependent signaling pathway in EpH4 and 293T cells
To conﬁrm that the T72A and T72S Cr-1 mutants are indeed
defective in their ability to activate a Nodal-dependent signal-ing pathway, we transfected 293T cells with a Nodal-respon-
sive luciferase reporter construct (n2)7-Lux together with
Cr-1 wild-type, T72A or T72S and Nodal in the presence of
Alk4 and FAST [13]. A 10-fold increase in luciferase activity
was observed in 293T cells co-transfected with wild-type Cr-1
and Nodal compared to control cells (P < 0.01) (Fig. 3A). In
contrast, the activity of both T72A and T72S Cr-1 mutants
was signiﬁcantly reduced compared to Cr-1 wild-type express-
ing cells (P < 0.01), conﬁrming that Thr72 in mouse Cr-1 is re-
quired for Cr-1-dependent Nodal signaling (Fig. 3A). We also
tested whether T72A and T72S Cr-1 mutants were able to in-
duce together with Nodal activation of Smad-2 in EpH4 mam-
mary epithelial. A Nodal expression vector was transiently
Fig. 3. T72A and T72S Cr-1 mutants fail to activate a Nodal-dependent signaling pathway in 293T and EpH4 cells. (A) Luciferase reporter assay in
293T cells transiently transfected with (n2)7-Lux reporter, FAST-1, Nodal, Alk4 expression vectors and Cr-1, T72A or T72S plasmids. *P < 0.01,
compared with control; **P < 0.01, compared to Cr-1. Data are representative of three experiments with triplicate samples. RLU: relative luciferase
units. (B) Western blot analysis for phospho- and total-Smad-2 in EpH4WT, Cr-1, T72A and T72S cells transiently transfected with Nodal. (C) Fold
diﬀerence in phospho-Smad-2 expression normalized to total-Smad-2 content by densitometric analysis. Densitometric analysis is representative of
three Western blot experiments. *P < 0.05, compared with control.
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and the levels of phosphorylated Smad-2 were examined by
Western blot analysis. The phospho-Smad-2 signal was en-
hanced by approximately 2.5-fold in EpH4 Cr-1 cells that were
transiently expressing Nodal, as compared to EpH4 WT cells
transfected with Nodal alone (Fig. 3B and C). In contrast,
Smad-2 phosphorylation was strongly reduced in EpH4
T72A or T72S cells that were expressing Nodal (Fig. 3B and
C).
3.5. T72A and T72S Cr-1 mutants bind to Glypican-1 in COS7
cells
Because we have previously demonstrated that Cripto-1 acti-
vates a Nodal and Alk4-independent signaling pathway
through Glypican-1 [7], we evaluated whether the T72A and
T72S Cr-1 mutants interact with Glypican-1. Wild-type,
T72A or T72S Cr-1 proteins were all found to interact to a
similar extent with Glypican-1 in a coimmunoprecipitation as-
say in COS7 cells (Fig. 4A). Western blot analysis of the cell
lysates for Cr-1 or Glypican-1 conﬁrmed expression of the
transfected plasmids in COS7 cells (Fig. 4B). To ascertain if
Glypican-1 is required by Cripto-1 to induce activation of
intracellular signaling molecules in mouse mammary epithelialcells, EpH4 WT, Cr-1, T72A or T72S cells were transfected
with a speciﬁc Glypican-1 siRNA or with a control non-silenc-
ing siRNA and analyzed by Western blot for activation of
MAPK and Akt signaling pathways. As shown in Fig. 4C,
transfection of Glypican-1 siRNA strongly reduced endoge-
nous Glypican-1 mRNA expression in EpH4 WT, Cr-1,
T72A or T72S cells as compared to cells transfected with a
control siRNA, as assessed by real-time PCR. Furthermore,
Western blot analysis showed a strong reduction in the phos-
phorylaion of MAPK (Fig. 4D) and Akt (Fig. 4F) in serum-
starved EpH4 Cr-1, T72A or T72S cells transfected with Glyp-
ican-1 siRNA as compared to cells transfected with a control
siRNA (Fig. 4E and G).4. Discussion
Several potential N-linked and O-linked glycosylation sites
have been identiﬁed within the protein structure of Cripto-1
[1]. O-fucosylation is a rare type of glycosylation that occurs
on Ser or Thr residues in the context of EGF repeats [8]. Cri-
pto-1 is fucosylated at a conserved Thr residue in the EGF-like
domain and a single point mutation in the fucosylation con-
Fig. 4. Glypican-1 is required by wild-type, T72A or T72S Cr-1 to activate MAPK and Akt signaling molecules in EpH4 cells. (A)
Immunoprecipitation for Glypican-1 in COS7 cells transiently transfected with Glypican-1-Fc alone or in combination with Cr-1, T72A or T72S and
Western blot analysis with an anti-Cr-1 antibody or anti-human Fc antibody. (B) Western blot analysis for Cr-1 and Glypican-1 on cell lysates of
COS7 transfected cells. (C) Real-time PCR for Glypican-1 in EpH4 WT, Cr-1, T72A or T72S cells transfected with control or Glypican-1 siRNAs.
Data were normalized to 28S mRNA expression. Data are representative of two experiments with duplicate samples. *P < 0.05. Western blot analysis
for phospho- and total-MAPK in serum-starved EpH4 cells transfected with Glypican-1 siRNA (D) or control siRNA (E). Western blot analysis for
phospho- and total-Akt in serum-starved EpH4 cells transfected with Glypican-1 siRNA (F) or control siRNA (G).
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facilitate Cripto-1-dependent Nodal signaling [9]. However,
subsequent studies revealed that fucosylation is not required
by Cripto-1 to function in a Nodal signaling assay [10]. For
example, embryos that are null for GDP-fucose protein O-fucosyltransferase-1 (Pofut1) expression, which is the enzyme
responsible for the addition of O-fucose to EGF repeats, die
at day 9.5, two days later than Cr-1 null embryos [14]. In addi-
tion, Cr-1, although not fucosylated in Pofut1/ embryonic
stem (ES) cells, can still activate a Nodal-dependent signaling
4002 C. Bianco et al. / FEBS Letters 582 (2008) 3997–4002pathway [10]. Furthermore, Pofut1/ or T72A mutant ES
cells can also diﬀerentiate into beating cardiomyocytes, a pro-
cess that requires a functional Cripto-1/Nodal signaling path-
way [10,15]. In contrast, the Thr residue to which O-fucose is
attached is absolutely required for Cr-1 function in a Nodal-
dependent signaling assay. In fact, site directed mutagenesis
of Thr72 with eight other amino acids or substitution with a
Ser residue, that can bind O-fucose, give rise to Cr-1 mutants
with a strongly impaired activity in Nodal assays. However, all
these studies lack any description of activity of Cripto-1
fucosylation or Thr mutants in a Nodal-independent signaling
pathway(s). Cripto-1 can function as an oncogene promoting
cellular proliferation and transformation in vitro and in vivo
mainly through activation of the ras/raf/MAPK and PI3K/
Akt signaling pathways [1,2,7]. In fact, treatment of mammary
epithelial or endothelial cells with speciﬁc MAPK or PI3K
inhibitors strongly interferes with the ability of Cr-1 to en-
hance proliferation, migration and invasion of these cells
[4,6,7]. On the contrary, an Alk4 inhibitor has very little eﬀect
on the migratory behavior of endothelial cells, suggesting that
these biological eﬀects of Cr-1 are mainly dependent on activa-
tion of a Nodal-independent signaling pathway [6]. In the pres-
ent study we demonstrate for the ﬁrst time that mutation of
Thr72 in mouse Cr-1 give rise to a fully functional protein with
respect to activation of a Nodal-independent signaling path-
way, whereas Thr72 is still required for the Cripto-1 Nodal-
dependent pathway. Because the EGF-like domain of Cr-1 di-
rectly interacts with Nodal, Thr72 is required for binding of Cr-
1 to Nodal [11]. Interaction of Cr-1 with Glypican-1 might be
also mediated by the EGF-like domain, since a peptide corre-
sponding to the EGF-like domain of Cr-1 results in activation
of MAPK signaling pathway downstream of Glypican-1 [1].
However, Thr72 mutation does not appear to perturb binding
of Cr-1 to Glypican-1 (Fig. 4A) and the subsequent activation
of MAPK and Akt signaling pathways in EpH4 cells (Fig. 2D
and E). Probably, diﬀerent amino acid residues within the
EGF-like domain mediate interaction of Cr-1 with Glypican-
1. Moreover, we demonstrate that Glypican-1 is absolutely re-
quired by both wild-type and T72A or T72S mutant Cr-1 pro-
teins to fully induce activation of MAPK and Akt signaling
pathways in EpH4 cells (Fig. 4D and F). Parisi and coauthors
have shown that glycine 71 and phenylalanine 78 in the EGF-
like domain and thryptophan 107 in the CFC domain of Cr-1
are required for cardiac diﬀerentiation of ES cells through a
Nodal-dependent signaling pathway [15]. It would be informa-
tive to assess if these Cr-1 mutants are also essential for inter-
action with Glypican-1 and activation of a Nodal-independent
signaling pathway. In this regard, a recent report by DAndrea
et al. has demonstrated that Cr-1 mouse embryos carrying the
amino acid substitution phenylalanine 78 to alanine (F78A),
which fail to stimulate a canonical Nodal-dependent pathway,
are able to establish an A/P axis, initiate germ layer formation
and gastrulation movements, unlike Cr-1 null embryos, prob-
ably through activation of a Nodal-independent signaling
pathway [16]. In conclusion, identiﬁcation of amino acid resi-
dues within Cripto-1 protein with diﬀerent binding aﬃnities
for signaling partners might be useful in deﬁning the mecha-nism by which Cripto-1 can activate in a selective manner a
Nodal-dependent versus a Nodal-independent pathway lead-
ing to a variety of biological responses.
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